Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
2010
Circadian oscillation of nucleotide excision repair in mammalian brain
2009 StandoutNobel
Loss of cryptochrome reduces cancer risk in p53 mutant mice
2009 StandoutNobel
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
2006
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial
2006
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
2007
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Cryptochrome, Circadian Cycle, Cell Cycle Checkpoints, and Cancer
2005 StandoutNobel
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004
Triple-Negative Breast Cancer
2010 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Regulation of nucleotide excision repair activity by transcriptional and post-transcriptional control of the XPA protein
2010 StandoutNobel
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data
2007
Metagenomic biomarker discovery and explanation
2011 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Circadian clock control of the cellular response to DNA damage
2010 StandoutNobel
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Host Circadian Clock as a Control Point in Tumor Progression
2002
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Is there a Reliable Method to Assess the Complete Pathologic Response on the Tumor after Neo-adjuvant Chemotherapy in Inflammatory Breast Cancer toward Recommendations for the Pathologic Process? Experience in 56 Patients Treated in a Single Institution
2010
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Modes of resistance to anti-angiogenic therapy
2008 Standout
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
2009 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
2013 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
2007
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
2005
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment
2005
Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
2003
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
2008
A circadian gene expression atlas in mammals: Implications for biology and medicine
2014 Standout
Circadian Rhythms: Mechanisms and Therapeutic Implications
2007
Control of skin cancer by the circadian rhythm
2011 StandoutNobel
Circadian Timing in Cancer Treatments
2010
Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
2005
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Circadian Clock, Cancer, and Chemotherapy
2014 StandoutNobel
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of S. Amat being referenced
Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
2003
Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome
2003
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate
2003
Relationship Between Circadian Rhythm of Vinorelbine Toxicity and Efficacy in P388-Bearing Mice
1999
Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy
2002
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
2002
Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy
2002